Nephrology's Future: New Drugs, Dialysis Advances, and Organ Solutions

Kidney diseases, including chronic kidney disease (CKD) and lupus nephropathy, represent a significant global health burden, often leading to end-stage renal disease requiring dialysis or transplantation. Patients with type 2 diabetes are particularly vulnerable to CKD progression. Despite existing treatments, there remains a critical need for more effective therapies to prevent disease progression, manage complications, and address the severe shortage of donor organs. This review addresses the latest advancements and emerging strategies poised to transform nephrology care in the near future.

The review highlighted several key breakthroughs: Complement inhibitors are expanding their indications across various kidney pathologies. For type 2 diabetes patients, semaglutide was found to prevent chronic kidney disease (CKD), while retatrutide significantly reduces albuminuria (protein in urine) in those with diabetes and established CKD. Obinutuzumab demonstrated improved renal response in patients suffering from lupus nephropathy. A double dose of icodextrin in peritoneal dialysis did not reduce mortality, peritonitis, or hospitalization rates compared to standard treatment, though it did increase ultrafiltration. Furthermore, using a dialysate with an intermediate potassium concentration combined with a potassium chelator in hemodialysis patients appears to stabilize serum potassium levels and reduce the occurrence of arrhythmias. Finally, xenotransplantation (animal-to-human organ transplant) and ex vivo perfusion (organ preservation outside the body) techniques are rapidly advancing, offering potential solutions to the critical organ shortage.